BioLife Solutions (BLFS) revenue breakdown
By product, Product, Cell Processing is the largest at 89% of fiscal 2024 revenue, growing 26% a year over 5 years.
Revenue by product
Fiscal years, as BioLife Solutions reports them in its 10-K filings; fiscal 2024 total $82M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|
| Product, Cell Processing | $23M | $31M | $45M | $69M | $66M | $73M | 89% |
| Rental, Evo and thaw | — | — | — | $4M | $7M | $6M | 7% |
| Product, Evo and thaw | — | — | — | $3M | $3M | $3M | 3% |
| Service, Evo and thaw | — | — | — | $73,000 | $349,000 | $160,000 | 0% |
| Freezer and thaw | $3M | $14M | $57M | — | — | — | — |
| Biostorage services | — | $2M | $10M | — | — | — | — |
| Biostorage services | $527,000 | $2M | $7M | — | — | — | — |
| Biostorage services | $165,000 | $46,000 | $328,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BLFS.
Open BLFS in InvestinglyQuestions
Where does BioLife Solutions make its money?
In fiscal 2024, by product: Product, Cell Processing $73M, Rental, Evo and thaw $6M, Product, Evo and thaw $3M, Service, Evo and thaw $160,000.
From BioLife Solutions's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.